Table 2. Guidance or support considered important to reduce the impact of COVID-19 on testing for HIV, HBV, HCV and STIsa, by setting, in 34 WHO European Region countries, March–August 2020 (n = 98 respondents).
| Community level sites (n = 52) |
Secondary level care sites (n = 36) |
National level (n = 10) |
|
|---|---|---|---|
| Additional human resources | 23 | 16 | 1 |
| Increased financial support | 35 | 13 | 1 |
| Regulatory changes | 16 | 2 | 0 |
| Programmatic guidance | 4 | 1 | 2 |
| Technical guidance | 6 | 3 | 1 |
| Technical support on specific issue | 5 | 4 | 1 |
| Procurement/supply chain related support | 6 | 4 | 1 |
| Other | 4 | 2 | 0 |
| None | 7 | 5 | 4 |
COVID-19: coronavirus disease; HBV hepatitis B virus; HCV hepatitis C virus; STIs: sexually transmitted infections; WHO: World Health Organization.
a Chlamydia, syphilis and gonorrhoea.